Nicox Provides Full Year 2024 Financial Results

Press ReleaseNicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA's future revenue stream to Soleus CapitalNicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is currently financed into the fourth quarter of 2025 Topline results from NCX 470 second Phase 3 clinical trial, Denali, expected in the third quarter of 2025...

Biot, 30/04/2025 (informazione.news - comunicati stampa - salute e benessere)

 

 

Income Statement

Balance sheet

Attachment